MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Search

Simulations Plus Inc

Chiusa

SettoreSettore sanitario

11.95 -0.17

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

11.93

Massimo

12.05

Metriche Chiave

By Trading Economics

Entrata

1.4M

676K

Vendite

961K

18M

Rendimento da dividendi

0.48

Margine di Profitto

3.67

Dipendenti

212

EBITDA

-3M

2.3M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+58.47% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

0.48%

2.45%

Utili prossimi

9 apr 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-139M

229M

Apertura precedente

12.12

Chiusura precedente

11.95

Notizie sul Sentiment di mercato

By Acuity

58%

42%

293 / 349 Classifica in Healthcare

Simulations Plus Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

3 apr 2026, 04:27 UTC

Principali Notizie su Eventi

Singapore PM Warns That Fallout From Mideast War Could Outlast Conflict

3 apr 2026, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

3 apr 2026, 18:30 UTC

Principali Notizie su Eventi

An F15-E Just Went Down in Iran. What to Know About the $30 Million Jet. -- Barrons.com

3 apr 2026, 18:14 UTC

Discorsi di Mercato

Eli Lilly Seen as Possible GLP-1 Leader With New Pill Approval -- Market Talk

3 apr 2026, 17:50 UTC

Discorsi di Mercato

Microsoft's AI Development Will Weigh on Near-Term Azure Growth -- Market Talk

3 apr 2026, 17:44 UTC

Acquisizioni, Fusioni, Takeovers

SBA Stock Just Had a Big Day. Why It's Suddenly Hot. -- Barrons.com

3 apr 2026, 16:50 UTC

Principali Notizie su Eventi

An F15-E Just Went Down in Iran. What to Know About the $90 Million Jet. -- Barrons.com

3 apr 2026, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

3 apr 2026, 16:12 UTC

Utili

Oil Stocks Look Tapped Out. Why It's Time to Move Into Other Sectors. -- Barrons.com

3 apr 2026, 15:56 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Crypto Markets May Be Active Over Holiday Weekend -- Market Talk

3 apr 2026, 15:56 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Global Equities Roundup: Market Talk

3 apr 2026, 15:56 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Global Forex and Fixed Income Roundup: Market Talk

3 apr 2026, 15:20 UTC

Principali Notizie su Eventi

Berkshire, Travelers Join U.S. Plan to Insure Shippers in the Hormuz Strait -- Barrons.com

3 apr 2026, 15:08 UTC

Acquisizioni, Fusioni, Takeovers

OpenAI Makes Surprise Media Acquisition Ahead of IPO. Why It Will Fail. -- Barrons.com

3 apr 2026, 14:11 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Oil Shock From War in Iran May Show Up In 2Q Job Growth Data -- Market Talk

3 apr 2026, 12:56 UTC

Discorsi di Mercato

Treasury Yields, Dollar Higher Following Robust March Hiring -- Market Talk

3 apr 2026, 08:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

3 apr 2026, 08:01 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

3 apr 2026, 08:01 UTC

Discorsi di Mercato

Meituan's Profitability Likely to Improve This Year -- Market Talk

3 apr 2026, 07:45 UTC

Discorsi di Mercato

LG Electronics Could Post Above-Consensus 1Q Earnings -- Market Talk

3 apr 2026, 06:17 UTC

Discorsi di Mercato

Naver Likely to Post Below-Consensus 1Q Earnings -- Market Talk

3 apr 2026, 06:17 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

3 apr 2026, 04:33 UTC

Discorsi di Mercato

China Merchants Port Earnings Likely to Recover This Year -- Market Talk

3 apr 2026, 04:33 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

3 apr 2026, 04:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

3 apr 2026, 04:01 UTC

Discorsi di Mercato

Posco Holdings 1Q Earnings Could Fall Short of Expectations -- Market Talk

3 apr 2026, 02:01 UTC

Discorsi di Mercato

India Consumer-Staple Companies Likely to Post Broadly Steady 4Q Results -- Market Talk

3 apr 2026, 01:59 UTC

Discorsi di Mercato

Sea's Shopee E-Commerce Platform Likely in Reinvestment Phase -- Market Talk

3 apr 2026, 01:44 UTC

Discorsi di Mercato

Samsung Likely to Report Record Quarterly Earnings in 2026 -- Market Talk

3 apr 2026, 01:22 UTC

Discorsi di Mercato

Dollar Could Hit 160 Yen in Thin Holiday Trading -- Market Talk

Confronto tra pari

Modifica del prezzo

Simulations Plus Inc Previsione

Obiettivo di Prezzo

By TipRanks

58.47% in crescita

Previsioni per 12 mesi

Media 19 USD  58.47%

Alto 19 USD

Basso 19 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Simulations Plus Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

4 ratings

2

Acquista

2

Mantieni

0

Vendi

Sentiment

By Acuity

293 / 349 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat